Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Radium-223 chloride - Bayer HealthCare

Next Previous
Drug Profile

Radium-223 chloride - Bayer HealthCare

Alternative Names: AC1O4D1M; Alpharadin; ATI-BC-1; BAY88-8223; Ra-223; Radium Ra 233 dichloride; Radium-223; Radium-223 dichloride; Xofigo; XofigoR

Latest Information Update: 27 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Algeta
  • Developer Algeta; Bayer HealthCare; Janssen; Medica Scientia Innovation Research; Royal Marsden NHS Foundation Trust; Sheffield Teaching Hospitals NHS Foundation Trust; The Institute of Cancer Research; Thomas Jefferson University; University of Texas M. D. Anderson Cancer Center
  • Class Analgesics; Antineoplastics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Bone metastases
  • Phase III Prostate cancer
  • Phase II Adenocarcinoma
  • Phase I/II Breast cancer; Non-small cell lung cancer
  • No development reported Osteosarcoma; Renal cell carcinoma
  • Discontinued Cancer pain; Multiple myeloma

Most Recent Events

  • 27 Oct 2025 Bayer completes a phase I trial in Bone metastases (Second-line therapy or greater, In adults, In the elderly) in Austria (IV), Finland (IV), France (IV), Germany (IV), Israel (IV), Italy (IV), United Kingdom (IV) (NCT04521361)
  • 30 Aug 2024 Phase-II clinical trials in Adenocarcinoma (Second-line therapy or greater) in USA (IV) (NCT05924672)
  • 08 Feb 2024 Bayer compltes a phase III trial in Bone metastases (from castration-resistant, chemotherapy-naive prostate cancer; first-line therapy, combination therapy) in US, Canada, the UK, Finland, Germany, Israel, Singapore, Spain, Norway, Italy, Sweden, Belgium, the Netherlands, Poland, Australia, Brazil, France and Japan (IV) (NCT02043678)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top